RNA Therapeutics Market Size & Growth Forecast 2027–2036, By Segments (Product, Indication, Type, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
RNA Therapeutics Market size was assessed at USD 22.13 Billion in 2026 and is poised to grow at 6.04% CAGR between 2027 and 2036, exceeding USD 39.78 Billion by 2036. The industry revenue for 2027 is calculated at USD 23.27 Billion.
Get more details on this report
Request Free Sample ReportRNA Therapeutics Market Intelligence Snapshot
Regional Market Dynamics
- North America held 38.88% in 2026, supported by strong biotechnology research, advanced healthcare infrastructure, clinical capabilities, and investment in novel therapeutic development.
- Asia Pacific is anticipated to grow fastest as biotechnology capabilities, healthcare investment, clinical research infrastructure, and domestic biopharmaceutical ecosystems expand.
Segment Momentum
- Vaccines accounted for 68.83% of the market in 2026 and remained the fastest-growing product segment due to rapid development, adaptability, and continued advances in RNA delivery technologies and manufacturing capabilities.
- RNAi therapeutics are gaining momentum as research increasingly targets gene-silencing therapies for genetic and chronic disorders, supported by advances in delivery technologies and growing interest in precision medicine.
Market Expansion Drivers
- Advancements in RNA delivery technologies improving therapeutic effectiveness and safety
- Rising incidence of infectious diseases increasing demand for RNA-based treatments
- Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines
Leading Market Participants
- Key players in the RNA therapeutics market include Moderna, Inc. (United States), BioNTech SE (Germany), Alnylam Pharmaceuticals, Inc. (United States), Ionis Pharmaceuticals, Inc. (United States), Pfizer Inc. (United States), Novartis AG (Switzerland), Sanofi S.A. (France), Sarepta Therapeutics, Inc. (United States), Arrowhead Pharmaceuticals, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 22.13 Billion
- 2027 Estimated Market Size: USD 23.27 Billion
- Projected Market Size: USD 39.78 Billion by 2036
- Growth Forecast: 6.04% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Vaccines (Product) | Infectious Diseases (Indication) | mRNA Therapeutics (Type) | Hospitals (End-use)
- Emerging Opportunity Segment: Vaccines (Product) | Infectious Diseases (Indication) | RNA Interference (RNAi) Therapeutics (Type) | Academic & Research Institutes (End-use)
Market Growth Drivers and Industry Trends
Advancements in RNA delivery technologies improving therapeutic effectiveness and safety
Continuous innovation in targeted delivery platforms will drive the RNA therapeutics market growth by improving the stability, precision, and safety of RNA-based treatments. Advanced delivery technologies are helping therapeutic molecules reach intended cells and tissues more efficiently while minimizing degradation and reducing unwanted biological effects. These improvements are expanding the feasibility of RNA therapeutics across a broader range of diseases and encouraging greater investment in the development of next-generation treatment platforms with enhanced clinical performance.
Rising incidence of infectious diseases increasing demand for RNA-based treatments
The increasing prevalence of infectious diseases will propel the RNA therapeutics market growth as healthcare systems prioritize rapid therapeutic development for emerging and recurring pathogens. RNA-based technologies provide flexible platforms that enable researchers to respond efficiently to evolving disease threats through adaptable treatment strategies. This capability is encouraging pharmaceutical developers to strengthen research programs focused on innovative RNA therapeutics capable of addressing infectious diseases with improved precision and accelerated development pathways.
Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines
The growing adoption of precision medicine is strengthening the RNA therapeutics market by supporting therapies designed around individual genetic and molecular characteristics. RNA-based treatments are increasingly being incorporated into personalized healthcare strategies because they can selectively target disease-related biological pathways while complementing advances in genomic analysis and molecular diagnostics. Collaboration between biotechnology companies, research institutions, and healthcare providers is also accelerating the expansion of RNA therapeutic pipelines focused on highly targeted treatment approaches for diverse medical conditions.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Advancements in RNA delivery technologies improving therapeutic effectiveness and safety | 2% | High | North America, Europe | High | Mid Term |
| Rising incidence of infectious diseases increasing demand for RNA-based treatments | 1.8% | High | North America, Asia Pacific | High | Near Term |
| Expanding precision medicine initiatives accelerating RNA therapeutic development pipelines | 1.5% | High | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of 38.88% in the RNA therapeutics market in 2026, underpinned by strong biotechnology research capabilities, advanced healthcare infrastructure, and significant activity in novel therapeutic development. RNA-based approaches are gaining attention for their potential to address a broad range of diseases through targeted biological mechanisms, supporting continued research and development across the region. Established clinical research capabilities and investment in advanced drug development technologies are facilitating progress from early-stage discovery toward therapeutic applications. Increasing interest in precision medicine and innovative treatment modalities is also strengthening the regional ecosystem for RNA-based therapies.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is anticipated to experience the fastest growth, supported by expanding biotechnology capabilities, rising healthcare investment, and increasing research activity focused on advanced therapeutics. Improvements in clinical research infrastructure and the development of domestic pharmaceutical and biotechnology ecosystems are creating favorable conditions for RNA therapeutic development. Growing demand for innovative treatments and greater emphasis on addressing complex and chronic diseases are further encouraging investment in emerging therapeutic platforms. In addition, efforts to strengthen local biopharmaceutical manufacturing and research capabilities are expected to expand the adoption and development of RNA-based therapeutic technologies across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced Clinical DevelopmentThe U.S. continues expanding RNA therapeutics through active clinical development, manufacturing innovation, and strategic industry collaboration. Pharmaceutical companies in the U.S. prioritize scalable production capabilities and diversified therapeutic pipelines across multiple disease areas.
Germany 🇩🇪
Translational Research StrengthGermany supports RNA therapeutics through strong collaboration between research organizations and pharmaceutical manufacturers. Companies in Germany continue advancing delivery technologies and production capabilities that improve the transition from laboratory research to clinical application.
Japan 🇯🇵
Precision Medicine AlignmentJapan advances RNA therapeutics by integrating innovative nucleic acid technologies into precision medicine strategies. Pharmaceutical developers in Japan emphasize product quality, targeted delivery, and collaboration with research institutions to expand therapeutic applications.
South Korea 🇰🇷
Biopharma Commercial ExpansionSouth Korea strengthens RNA therapeutics through expanding biopharmaceutical manufacturing capacity and technology partnerships. Companies in South Korea continue investing in platform development that supports efficient production and broader therapeutic commercialization.
France 🇫🇷
Collaborative Therapeutic InnovationFrance encourages RNA therapeutics development through partnerships between biotechnology firms, research centers, and healthcare organizations. Organizations in France prioritize delivery technologies and translational research that support broader clinical adoption.
Italy 🇮🇹
Academic Research TranslationItaly focuses on translating RNA therapeutics research into clinically relevant applications through collaboration between academic institutions and biotechnology companies. The innovation ecosystem in Italy increasingly supports manufacturing readiness and therapeutic development across specialized disease areas.
Segment Leadership and Growth Trends
RNA Therapeutics Market Share (%), Product, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProduct Segment Analysis: Vaccines (Largest & Fastest-Growing Segment)
The RNA therapeutics market was led by the vaccines segment, which accounted for 68.83% in 2026 while also emerging as the fastest-growing product category. The segment continues to benefit from the growing adoption of RNA-based vaccine technologies due to their rapid development timelines, high adaptability, and ability to address emerging infectious threats. Continuous advancements in RNA delivery platforms, manufacturing capabilities, and therapeutic research have strengthened confidence in RNA vaccines for both infectious disease prevention and broader clinical applications. Ongoing investments in next-generation vaccine development and expanding research pipelines are expected to further reinforce the segment's dominant position.
Indication Segment Analysis: Infectious Diseases (Largest & Fastest-Growing Segment)
The RNA therapeutics market was dominated by the infectious diseases indication segment, which secured 59.9% in 2026 while also recording the fastest growth. Increasing global efforts to prevent and manage infectious diseases have accelerated the adoption of RNA-based therapeutic approaches capable of delivering rapid and targeted immune responses. The expanding focus on pandemic preparedness, continuous innovation in RNA technologies, and growing investment in infectious disease research continue to strengthen demand within this indication. Broadening clinical applications and sustained research activity are expected to support the segment's continued leadership.
Type Segment Analysis: mRNA Therapeutics (Largest Segment) vs RNA Interference (RNAi) Therapeutics (Fastest-Growing Segment)
Holding the largest share of the RNA therapeutics market, the mRNA therapeutics segment captured 62.98% in 2026. The widespread adoption of messenger RNA technologies has been driven by their ability to direct targeted protein production while offering flexibility for the development of vaccines and therapeutic treatments across multiple disease areas. Continuous advancements in delivery systems and manufacturing processes have further expanded the commercial and clinical potential of mRNA-based therapeutics.
The RNA interference (RNAi) therapeutics segment is expected to witness the fastest growth as increasing research efforts focus on therapies capable of selectively silencing disease-causing genes. RNAi technology offers a highly targeted treatment approach for a broad range of genetic and chronic disorders, encouraging greater investment in clinical development. Improvements in delivery technologies and growing interest in precision medicine are expected to accelerate the adoption of RNAi therapeutics over the coming years.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Product | Vaccines, Drugs | Vaccines | Vaccines |
| Indication | Infectious Diseases, Hereditary/genetic Diseases, Autoimmune Disorders, Others | Infectious Diseases | Infectious Diseases |
| Type | mRNA Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, siRNA (small Interfering RNA) Therapeutics, RNA Interference (RNAi) Therapeutics, Others | mRNA Therapeutics | RNA Interference (RNAi) Therapeutics |
| End-use | Hospitals, Academic & Research Institutes, Others | Hospitals | Academic & Research Institutes |
Competitive Landscape and Market Positioning
Key companies in the RNA therapeutics market:
- Moderna, Inc. (United States)
- BioNTech SE (Germany)
- Alnylam Pharmaceuticals, Inc. (United States)
- Ionis Pharmaceuticals, Inc. (United States)
- Pfizer, Inc. (United States)
- Novartis AG (Switzerland)
- Sanofi S.A. (France)
- Sarepta Therapeutics, Inc. (United States)
- Arrowhead Pharmaceuticals, Inc. (United States)
- Regeneron Pharmaceuticals, Inc. (United States)
Scientific progress is steadily redirecting competitive focus from demonstrating therapeutic potential to building platforms that improve delivery efficiency, molecular stability, and manufacturing reproducibility across multiple therapeutic applications. Organizations are investing heavily in technologies that enable broader clinical applicability while addressing formulation and targeted delivery challenges that have historically limited wider adoption. As development programs become more sophisticated, competition increasingly favors participants that can integrate scalable production processes with strong regulatory readiness, allowing promising therapeutic candidates to advance more efficiently through increasingly demanding development pathways.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Macquarie University | Apr-26 | Macquarie University opened Australia's first 4,500-square-meter RNA manufacturing facility. Equipped with GMP-compliant cleanrooms capable of producing mRNA, synthetic RNA, and lipid nanoparticle formulations, this infrastructure investment significantly bolsters regional domestic manufacturing capacity for RNA therapeutics and reduces reliance on international supply chains for critical research and clinical-grade materials. |
| Vivatides Therapeutics | Apr-26 | Vivatides Therapeutics raised US$54 million in an oversubscribed Series A financing round. The capital will be deployed to expand its platform for extrahepatic RNA-targeting therapeutics and to accelerate the progression of its pipeline into new, underserved disease areas, reflecting continued investor interest in targeted RNA delivery technologies. |
| Atrium Therapeutics | Feb-26 | Atrium Therapeutics launched as an independent biotechnology firm with US$270 million in funding following the Novartis–Avidity transaction. The company will focus on the development of specialized RNA therapeutics targeting rare genetic cardiomyopathies, signaling a new entrant into the high-value rare disease segment of the RNA therapeutics market. |
| Acuitas Therapeutics | Jan-26 | Acuitas Therapeutics acquired a majority stake in RNA Technologies & Therapeutics to enhance its internal manufacturing capabilities. The move is strategically aimed at securing high-quality, scalable production of RNA constructs, which are essential components for developing and commercializing advanced gene and RNA-based therapies. |
| Kolon Life Science | Nov-25 | Kolon Life Science expanded its pharmaceutical materials portfolio to include phosphoramidite production. By domesticating the supply of this critical raw material, the company aims to strengthen the supply chain resilience and manufacturing stability for RNA therapeutics developers, mitigating risks associated with external sourcing of oligonucleotide synthesis reagents. |
| Novartis | Oct-25 | Novartis agreed to acquire Avidity Biosciences for approximately US$12 billion, a strategic transaction that significantly expands the company's RNA therapeutics portfolio and integrates advanced RNA-targeted drug development programs into its existing research and commercial framework. |
| Eli Lilly and Company | May-25 | Eli Lilly and Company entered a strategic collaboration with Rznomics valued at up to US$1.3 billion to develop novel RNA-based therapies for hearing loss. This partnership underscores the company’s commitment to expanding its internal RNA medicine pipeline through targeted external innovation and therapeutic co-development. |
| Eli Lilly and Company | Apr-25 | Eli Lilly and Company formed a research collaboration with Creyon Bio worth up to US$1 billion to develop AI-enabled oligonucleotide therapeutics. This initiative is designed to strengthen the company’s RNA therapeutics discovery capabilities by leveraging advanced machine learning to accelerate the design and development of precision medicines. |
| EnPlusOne Biosciences | Feb-25 | EnPlusOne Biosciences raised approximately US$10 million to scale its enzymatic RNA synthesis platform. This investment is directed toward transitioning from laboratory-scale research to larger-scale production, addressing current industry bottlenecks in the cost-effective and efficient manufacturing of RNA for broad therapeutic applications. |
| etherna | Jan-25 | etherna partnered with Dropshot in a collaboration valued at up to US$950 million, combining mRNA and lipid nanoparticle (LNP) technologies. The agreement aims to accelerate the development of specialized RNA medicines specifically targeting cardiac and renal diseases, expanding the reach of current mRNA delivery platforms into these critical therapeutic areas. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
RNA Therapeutics Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
RNA Therapeutics Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the market valuation of RNA therapeutics?
What is the forecasted size of the RNA therapeutics industry?
How are advances in RNA delivery technologies influencing therapeutic development?
What is driving the expansion of RNA therapeutics development pipelines?
Why do RNA vaccines lead the RNA therapeutics market?
Why are RNA interference (RNAi) therapeutics the fastest-growing type segment?
Which factors support North America’s leadership in RNA therapeutics?
How is Asia Pacific strengthening its position in RNA therapeutics?
Which companies dominate the RNA therapeutics landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization